Fed. Circ. Erases $41.8M Verdict Over Seagen Cancer Drug IP
By Adam Lidgett · December 2, 2025, 4:53 PM EST
The Federal Circuit in a precedential opinion Tuesday reversed a $41.8 million verdict against Daiichi Sankyo for infringing a Seagen breast cancer treatment patent, saying a lower court should have found...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login